Monte Rosa Therapeutics (GLUE) Competitors $4.16 +0.05 (+1.22%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. RCUS, SYRE, ELVN, PHVS, AVDL, NAGE, NTLA, ARDX, CRMD, and CMRXShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Pharvaris (PHVS), Avadel Pharmaceuticals (AVDL), Niagen Bioscience (NAGE), Intellia Therapeutics (NTLA), Ardelyx (ARDX), CorMedix (CRMD), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Arcus Biosciences Spyre Therapeutics Enliven Therapeutics Pharvaris Avadel Pharmaceuticals Niagen Bioscience Intellia Therapeutics Ardelyx CorMedix Chimerix Monte Rosa Therapeutics (NASDAQ:GLUE) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do analysts rate GLUE or RCUS? Monte Rosa Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 272.60%. Arcus Biosciences has a consensus price target of $25.67, indicating a potential upside of 189.69%. Given Monte Rosa Therapeutics' higher possible upside, research analysts plainly believe Monte Rosa Therapeutics is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91 Which has more volatility & risk, GLUE or RCUS? Monte Rosa Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Is GLUE or RCUS more profitable? Monte Rosa Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Arcus Biosciences' return on equity of -45.59% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Arcus Biosciences -102.66%-45.59%-22.38% Does the MarketBeat Community believe in GLUE or RCUS? Arcus Biosciences received 184 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 65.57% of users gave Arcus Biosciences an outperform vote while only 48.48% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1648.48% Underperform Votes1751.52% Arcus BiosciencesOutperform Votes20065.57% Underperform Votes10534.43% Which has higher valuation & earnings, GLUE or RCUS? Monte Rosa Therapeutics has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$159.49M1.60-$135.35M$0.0852.00Arcus Biosciences$141M6.65-$307M-$4.19-2.11 Does the media refer more to GLUE or RCUS? In the previous week, Arcus Biosciences had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 6 mentions for Arcus Biosciences and 5 mentions for Monte Rosa Therapeutics. Arcus Biosciences' average media sentiment score of 1.50 beat Monte Rosa Therapeutics' score of 1.45 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in GLUE or RCUS? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 6.9% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryArcus Biosciences beats Monte Rosa Therapeutics on 12 of the 19 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.88M$2.97B$5.42B$8.48BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-2.2731.5826.8320.05Price / Sales1.60429.55393.86119.28Price / CashN/A168.6838.2534.62Price / Book1.163.376.874.61Net Income-$135.35M-$72.17M$3.22B$248.19M7 Day Performance2.97%15.52%5.65%2.88%1 Month Performance-8.57%22.04%13.54%15.40%1 Year Performance-15.96%-24.88%18.16%7.68% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.218 of 5 stars$4.16+1.2%$15.50+272.6%-16.0%$255.88M$159.49M-2.2790Positive NewsRCUSArcus Biosciences3.5953 of 5 stars$8.57+0.3%$25.67+199.7%-47.4%$906.91M$141M-2.72500Gap UpSYRESpyre Therapeutics2.3601 of 5 stars$14.51-2.0%$53.40+268.0%-58.2%$875.57M$890,000.00-1.94100Positive NewsELVNEnliven Therapeutics2.5336 of 5 stars$17.77-10.7%$40.67+128.9%-27.6%$872.64MN/A-9.3650Earnings ReportAnalyst RevisionGap UpPHVSPharvaris1.3029 of 5 stars$16.35+1.7%$40.67+148.8%-16.5%$854.68MN/A-5.8430AVDLAvadel Pharmaceuticals2.2363 of 5 stars$8.73+2.3%$19.43+122.5%-40.3%$842.61M$169.12M-11.0470NAGENiagen BioscienceN/A$10.56+4.6%N/AN/A$830.90M$99.60M62.12120NTLAIntellia Therapeutics4.6731 of 5 stars$7.90+0.3%$36.90+367.1%-62.6%$819.65M$45.57M-1.45600Analyst ForecastARDXArdelyx4.5525 of 5 stars$3.38+2.9%$10.39+207.8%-47.3%$805.09M$361.71M-21.0390Insider TradeCRMDCorMedix2.15 of 5 stars$11.84+1.9%$15.00+26.7%+153.9%$802.03M$82.55M-14.6030CMRXChimerix0.5605 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst Forecast Related Companies and Tools Related Companies RCUS Alternatives SYRE Alternatives ELVN Alternatives PHVS Alternatives AVDL Alternatives NAGE Alternatives NTLA Alternatives ARDX Alternatives CRMD Alternatives CMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLUE Stock Free GLUE Stock Alerts